Worth reading
39Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Items stated in the management plan
Annual updateWhat happened to the previous plan¥500 million (fiscal 2025 earnings forecast revenue) → ¥593 million (revenue for the fiscal year ended December 2025)（More than 18.6%）0.0%Calculated from the two disclosed figures
Investment amount by sectorField CBA-1205 / Planned investment ¥240 million, Field CBA-1535 / Planned investment ¥290 million, Field Other drug discovery programs (PTRY, PCDC, PXLR, etc.) / Planned investment ¥610 million, Field Drug Discovery Support Business / Planned investment ¥50 million, Field IDD business: biosimilars / Planned investment ¥200 million, Field IDD business: support for pharmaceutical companies and startups / Planned investment Not disclosed, Field Technology Platform / Planned investment ¥340 million, Field ADCT-701、PFKR / Planned investment Not disclosed
Key initiatives
01Sustainable growth model based on a three-tier portfolio
02Drug discovery business: research and development of new drugs
03Drug discovery support business: second-lab research support services
04IDD: drug discovery platform services business
05Development plans for key pipeline programs and other initiatives
06Initiative to strengthen consortium-based startup incubation
07Launch of IDD and the positioning of IDD within the business segments
08Strengthening the functions of the IDD business
Size of the Target MarketMarket Global liver cancer therapeutics market / Scale US$2.0 billion in 2020 (US$2.038 billion as shown in the graph) to US$7.4 billion in 2027 (US$7.382 billion as shown in the graph) / Growth rate CAGR 20.2％ / Source Fortune Business Insights Pvt. Ltd.; Research Nester Private Limited, Market Global lung cancer therapeutics market / Scale US$28.0 billion in 2022 to US$59.6 billion in 2032 / Growth rate CAGR 7.9％ / Source Precedence Research
Reason for revision or withdrawal
To extend the monotherapy part and expand the data in anticipation of the possibility of out-licensing based solely on data from the monotherapy part. To increase the likelihood of successful development of this drug through early licensing to companies with strong development funding capabilities in the increasingly competitive solid-tumor T-cell engager field.
| Item | Details |
|---|---|
| Plan name | Business Plan and Growth Potential |
| Plan period | 2026–2027 |
| Progress against the plan | Annual update |
| Investment amount by sector | Field CBA-1205 / Planned investment ¥240 million, Field CBA-1535 / Planned investment ¥290 million, Field Other drug discovery programs (PTRY, PCDC, PXLR, etc.) / Planned investment ¥610 million, Field Drug Discovery Support Business / Planned investment ¥50 million, Field IDD business: biosimilars / Planned investment ¥200 million, Field IDD business: support for pharmaceutical companies and startups / Planned investment Not disclosed, Field Technology Platform / Planned investment ¥340 million, Field ADCT-701、PFKR / Planned investment Not disclosed |
| Key initiatives | Sustainable growth model based on a three-tier portfolio, Drug discovery business: research and development of new drugs, Drug discovery support business: second-lab research support services, IDD: drug discovery platform services business, Development plans for key pipeline programs and other initiatives, Initiative to strengthen consortium-based startup incubation, Launch of IDD and the positioning of IDD within the business segments, Strengthening the functions of the IDD business |
| Results under the previous plan | ¥500 million (fiscal 2025 earnings forecast revenue) → ¥593 million (revenue for the fiscal year ended December 2025)（More than 18.6%） |
| Reason for revision or withdrawal | To extend the monotherapy part and expand the data in anticipation of the possibility of out-licensing based solely on data from the monotherapy part. To increase the likelihood of successful development of this drug through early licensing to companies with strong development funding capabilities in the increasingly competitive solid-tumor T-cell engager field. |
| Size of the Target Market | Market Global liver cancer therapeutics market / Scale US$2.0 billion in 2020 (US$2.038 billion as shown in the graph) to US$7.4 billion in 2027 (US$7.382 billion as shown in the graph) / Growth rate CAGR 20.2％ / Source Fortune Business Insights Pvt. Ltd.; Research Nester Private Limited, Market Global lung cancer therapeutics market / Scale US$28.0 billion in 2022 to US$59.6 billion in 2032 / Growth rate CAGR 7.9％ / Source Precedence Research |
| Publication date | 23 March 2026 |
Items this document does not state (16)
Sales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planSegment targetNon-financial targetsPlan assumptionsRisks identifiedDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To expand the data on CBA-1535 in anticipation of the possibility of out-licensing based solely on data from the monotherapy part. In addition, to increase the likelihood of successful development in the increasingly competitive solid-tumor T-cell engager field through early licensing to companies with strong development funding capabilities.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.